PET-guided treatment and monitoring for limited-stage lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests a treatment approach guided by PET scans, plus non-invasive monitoring, for adults with limited-stage diffuse large B-cell lymphoma (a type of lymphoma). It may help by tailoring therapy based on scan and other follow-up information, aiming for better outcomes with fewer invasive steps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have not had treatment yet for limited-stage non-bulky diffuse large B-cell lymphoma (DLBCL), based on standard staging scans and bone marrow biopsy results
- Your cancer shows up on an FDG-PET scan (a special PET scan that highlights active disease)
- You can provide tumor tissue from a biopsy (archived tissue or a fresh/frozen sample)
- Your blood counts, heart, kidneys, and liver tests meet study limits
- You do not have “bulky” tumors larger than 10 cm in any one direction
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test (ctDNA) and PET scans to predict how well standard first-line treatment works for diffuse large B-cell lymphoma (DLBCL). It aims to find out if these tests can guide better care.
This study tests whether a computer-guided treatment plan can work as well as or better than the standard chemo-immunotherapy for large B-cell lymphoma. It uses a special test after the first cycle to decide who needs a more aggressive approach.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This study tests whether adding low-dose radiation to standard chemoimmunotherapy can improve outcomes for people with newly diagnosed large B-cell lymphoma, using a personalized blood test to guide who gets radiation. It may help reduce the risk of the lymphoma returning by targeting sites still showing signs of disease.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This study tests whether using PET scans and a simple blood test (called liquid biopsy) can quickly and accurately monitor how well your lymphoma is responding to standard first-line treatment. The goal is to see if these real-time monitoring tools can improve care for aggressive B-cell lymphomas.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.